<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052390</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258249</org_study_id>
    <secondary_id>MSKCC-02041</secondary_id>
    <secondary_id>NCI-2270</secondary_id>
    <nct_id>NCT00052390</nct_id>
  </id_info>
  <brief_title>Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma</brief_title>
  <official_title>A Multi-Institutional, Open-Label, Phase II Study Of Doxorubicin And Bevacizumab (Anti-VEFG Monoclonal Antibody, NSC 704865) For Patients With Advanced Or Metastatic Soft-Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Bevacizumab may stop the growth of tumor cells by stopping blood&#xD;
      flow to the tumor. Combining doxorubicin with bevacizumab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin with bevacizumab&#xD;
      in treating patients who have locally recurrent or metastatic soft tissue sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate (partial and complete) in patients with locally recurrent or&#xD;
           metastatic soft tissue sarcoma treated with doxorubicin and bevacizumab.&#xD;
&#xD;
        -  Determine the tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine whether pre-treatment plasma vascular endothelial growth factor level or&#xD;
           microvessel density of tumor samples from these patients predicts response to this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive doxorubicin IV over 5-10 minutes followed by bevacizumab IV over 30-90&#xD;
      minutes on day 1. Courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with responding disease after reaching the maximum dose of&#xD;
      doxorubicin may continue bevacizumab alone.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 17-37 patients will be accrued for this study within 13.3&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed soft tissue sarcoma&#xD;
&#xD;
               -  Locally recurrent or metastatic disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No prior or concurrent known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100% OR&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No bleeding diathesis or coagulopathy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.2 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  PT and aPTT normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No proteinuria (must be less than 500 mg protein per 24 hours)&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac ejection fraction at least 50% by echocardiogram or MUGA&#xD;
&#xD;
          -  No history of deep vein thrombosis&#xD;
&#xD;
          -  No clinically significant cardiovascular disease&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No myocardial infarction&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No New York Heart Association grade II-IV congestive heart failure&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  No grade II or greater peripheral vascular disease within the past year&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No history of pulmonary embolism&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  No other neoplastic disease within the past 5 years except curatively treated basal&#xD;
             cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to bevacizumab (including products derived from Chinese hamster ovary&#xD;
             cells), doxorubicin, or dexrazoxane&#xD;
&#xD;
          -  No HIV-positive patients receiving combination antiretroviral therapy&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situations that would preclude study entry&#xD;
&#xD;
          -  No other uncontrolled concurrent illness&#xD;
&#xD;
          -  No serious, non-healing wound ulcer or bone fracture&#xD;
&#xD;
          -  No significant traumatic injury within the past 3 weeks&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior doxorubicin or any other anthracyclines&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
               -  The following are not considered prior chemotherapy:&#xD;
&#xD;
                    -  Immunotherapy, including cytokines&#xD;
&#xD;
                    -  Peroxisome-proliferator-activated receptor gamma agonists or thalidomide&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for carmustine or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 3 weeks since prior major surgical procedure or open biopsy&#xD;
&#xD;
          -  At least 1 week since prior needle biopsy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent full-dose anticoagulants (except to maintain patency of preexisting,&#xD;
             permanent indwelling IV catheters) or thrombolytic agent&#xD;
&#xD;
               -  Concurrent warfarin allowed if INR less than 1.5&#xD;
&#xD;
          -  No concurrent chronic daily aspirin (more than 325 mg/day) or nonsteroidal anti&#xD;
             -inflammatory medications known to inhibit platelet function&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for this&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Maki, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H, Maki RG. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005 Oct 1;23(28):7135-42.</citation>
    <PMID>16192597</PMID>
  </results_reference>
  <verification_date>February 2004</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

